recent pharma news

Mar 05, 2020

Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients' T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain...

Mar 03, 2020

Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Forty Seven – named after its lead molecule - CD47 tumor cell protein - Gilead will acquire its lead candidate, Magrolimab, adding value to its ...

Feb 25, 2020

Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.  With the gree...

Feb 20, 2020

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxoliti...

Feb 13, 2020

J&J collaborates with BARDA to accelerate coronavirus vaccine program Johnson & Johnson has collaborated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce a vaccine against novel coronavirus. J&J is attempting to pool money and resources with BARDA in order to qu...

Feb 11, 2020

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle cell lymphoma (MCL) The drug- KTE-X19, which is an investigational chimeric antigen receptor (CAR) T cell therapy treatment method for curing relapsed or refractory mantle cell...

Feb 06, 2020

Activated immune cells responsible for improving age-related diseases  The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL-5. There has been researching going on, and the researchers at Albany Medical College discovered that if these two signalling molecules ...

Feb 04, 2020

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...

Jan 30, 2020

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...

Jan 28, 2020

The drug, sotatercept of Acceleron Pharma, touches the phase 2 mark Acceleron Pharma, a clinical-stage biopharmaceutical company based in Boston, Massachusetts with a primary aim on the development of medicines that regulate the transforming growth factor-beta (TGF-β) superfamily of proteins that play significan...